<!DOCTYPE HTML>

<!-- template-example-ttl.html -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
  <title>Medicinalproductindication-example.ttl - FHIR v3.5.0</title>

  
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <meta name="author" content="http://hl7.org/fhir"/>

  <link href="fhir.css" rel="stylesheet"/>
  <link rel="Prev" href="http://hl7.org/fhir/medicinalproductindication-example.ttl.html"/>

  <!-- Bootstrap core CSS -->
  <link href="./dist/css/bootstrap.css" rel="stylesheet"/>
  <link href="./assets/css/bootstrap-fhir.css" rel="stylesheet"/>

  <!-- Project extras -->
  <link href="./assets/css/project.css" rel="stylesheet"/>
  <link href="./assets/css/pygments-manni.css" rel="stylesheet"/>
	<link href="jquery-ui.css" rel="stylesheet"/>

  <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
  <!--[if lt IE 9]>
  <script src="./assets/js/html5shiv.js"></script>
  <script src="./assets/js/respond.min.js"></script>
  <![endif]-->

  <!-- Favicons -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="./assets/ico/apple-touch-icon-144-precomposed.png"/>
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="./assets/ico/apple-touch-icon-114-precomposed.png"/>
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="./assets/ico/apple-touch-icon-72-precomposed.png"/>
  <link rel="apple-touch-icon-precomposed" href="./assets/ico/apple-touch-icon-57-precomposed.png"/>
  <link rel="shortcut icon" href="./assets/ico/favicon.png"/>

</head>
<body>
	<div id="segment-header" class="segment"><!-- segment-header -->	
		<div class="container"><!-- container -->
			<a id="logo" href="http://hl7.org/fhir" no-external="true"><img src="./assets/images/fhir-logo-www.png" alt="logo fhir"/> </a>
			<div id="hl7-status">
				<b>Current Build</b>
			</div>       	
			
			<div id="hl7-nav">
				 <a id="hl7-logo" href="http://www.hl7.org" no-external="true">
					<img src="./assets/images/hl7-logo.png" width="42" height="50" alt="visit the hl7 website"/>
				</a> 
			</div>       	
			<div id="hl7-nav"><a id="hl7-logo" no-external="true" href="http://hl7.org/fhir/search.cfm"><img alt="Search FHIR" src="./assets/images/search.png"/></a></div> 
		</div>
		<div class="container"><!-- container -->
	</div></div><!-- /segment-header -->	


	<div id="segment-navbar" class="segment"><!-- segment-navbar -->
		<div id="stripe"> </div>
		<div class="container"><!-- container -->
 <!-- HEADER CONTENT -->
 	      		 	      		      		
			<nav class="navbar navbar-inverse">
				<div class="container">
					<button data-target=".navbar-inverse-collapse" data-toggle="collapse" class="navbar-toggle" type="button">
						<span class="icon-bar"> </span>
						<span class="icon-bar"> </span>
						<span class="icon-bar"> </span>
					</button>
					<a href="index.html" class="navbar-brand hidden">FHIR</a>
					<div class="nav-collapse collapse navbar-inverse-collapse">
						<ul class="nav navbar-nav">
              <li><a href="./index.html">Home</a></li>
              <li><a href="./modules.html">Getting Started</a></li>
              <li><a href="./documentation.html">Documentation</a></li>
              <li><a href="./resourcelist.html">Resources</a></li>
              <li><a href="./profilelist.html">Profiles</a></li>
              <li><a href="./extensibility-registry.html">Extensions</a></li>
              <li><a href="./operationslist.html">Operations</a></li>
              <li><a href="./terminologies-systems.html">Terminologies</a></li>
						</ul>
					</div><!-- /.nav-collapse -->
				</div><!-- /.container -->
			</nav><!-- /.navbar -->
      		
<!-- /HEADER CONTENT -->				
		</div><!-- /container -->
	</div><!-- /segment-navbar -->
	

	<div id="segment-breadcrumb" class="segment"><!-- segment-breadcrumb -->
		<div class="container"><!-- container -->	
			<ul class="breadcrumb">
        <li><a href="medications-module.html"><img src="medication.png"/> Medications</a></li>        <li><a href="medicinalproductindication.html">MedicinalProductIndication</a></li>        <li><b>Example Instance</b></li>        <!-- medicinalproductindication-example.ttl.html / resource-instance:MedicinalProductIndication / Example-->

			</ul>	
		</div><!-- /container -->
	</div><!-- /segment-breadcrumb -->
	

	<div id="segment-content" class="segment"><!-- segment-content -->
	<div class="container"><!-- container -->
            <div class="row">
            	<div class="inner-wrapper">
<!-- CONTENT CONTENT -->


<div class="col-12">

<h1>Medicinalproductindication-example.ttl</h1>
<table class="colsi"><tr><td><a href="http://www.hl7.org/Special/committees/rcrim/index.cfm">Biomedical Research and Regulation</a> Work Group</td><td><a href="versions.html#maturity">Maturity Level</a>: N/A</td><td id="ballot"><a href="ballot-intro.html#process">Ballot Status</a>: Informative</td><!--!ns!--><td><a href="compartmentdefinition.html">Compartments</a>: Not linked to any defined compartments</td></tr></table>

</tbody></table>
<p>
<a href="medicinalproductindication-example.ttl">Raw Turtle</a> (+ also see <a href="rdf.html">Turtle/RDF Format Specification</a>)
</p>

<div class="example">
<p>Example of medicinalproductindication</p>
<pre class="json">
@prefix fhir: &lt;http://hl7.org/fhir/&gt; .
@prefix owl: &lt;http://www.w3.org/2002/07/owl#&gt; .
@prefix rdfs: &lt;http://www.w3.org/2000/01/rdf-schema#&gt; .
@prefix xsd: &lt;http://www.w3.org/2001/XMLSchema#&gt; .

# - resource -------------------------------------------------------------------

&lt;http://hl7.org/fhir/MedicinalProductClinicals/example&gt; a fhir:MedicinalProductClinicals;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value &quot;example&quot;];
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value &quot;generated&quot; ];
     fhir:Narrative.div &quot;&lt;div xmlns=\&quot;http://www.w3.org/1999/xhtml\&quot;&gt;&lt;p&gt;&lt;b&gt;Generated Narrative with Details&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;id&lt;/b&gt;: example&lt;/p&gt;&lt;h3&gt;UndesirableEffects&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;td&gt;&lt;b&gt;SymptomConditionEffect&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;FrequencyOfOccurrence&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;td&gt;Prevention of\\nVTE in adult\\npatients who have\\nundergone\\nelective hip or\\nknee replacement\\nsurgery (VTEp) &lt;span&gt;(Details : {http://ema.europa.eu/example/undesirableeffectassymptom-condition-effect code 'Anaemia' = 'Anaemia)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Bloodandlymphaticsystemdisorders &lt;span&gt;(Details : {http://ema.europa.eu/example/symptom-condition-effectclassification code 'Bloodandlymphaticsystemdisorders' = 'Bloodandlymphaticsystemdisorders)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Common &lt;span&gt;(Details : {http://ema.europa.eu/example/frequencyofoccurrence code 'Common' = 'Common)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;blockquote&gt;&lt;p&gt;&lt;b&gt;therapeuticIndication&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;diseaseSymptomProcedure&lt;/b&gt;: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). &lt;span&gt;(Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;comorbidity&lt;/b&gt;: Hipsurgery &lt;span&gt;(Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;intendedEffect&lt;/b&gt;: PRYLX &lt;span&gt;(Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)&lt;/span&gt;&lt;/p&gt;&lt;h3&gt;Populations&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/blockquote&gt;&lt;h3&gt;Contraindications&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;td&gt;&lt;b&gt;Disease&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Comorbidity&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;td&gt;Hepatic disease associated with coagulopathy and clinically relevant bleeding risk &lt;span&gt;(Details : {http://ema.europa.eu/example/contraindicationsasdisease-symptom-procedure code 'Coagulopathiesandbleedingdiatheses(exclthrombocytopenic)' = 'Coagulopathiesandbleedingdiatheses(exclthrombocytopenic))&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Hepaticdisease &lt;span&gt;(Details : {http://ema.europa.eu/example/comorbidity code 'Hepaticdisease' = 'Hepaticdisease)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3&gt;Interactions&lt;/h3&gt;&lt;table&gt;&lt;tr&gt;&lt;td&gt;-&lt;/td&gt;&lt;td&gt;&lt;b&gt;Interaction&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Interactant&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Type&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Effect&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Management&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;*&lt;/td&gt;&lt;td&gt;Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.&lt;/td&gt;&lt;td&gt;ketoconazole &lt;span&gt;(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;StrongInhibitorofCYP3A4 &lt;span&gt;(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Increasedplasmaconcentrations &lt;span&gt;(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp &lt;span&gt;(Details : {http://ema.europa.eu/example/managementactions code 'CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp' = 'CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&quot;
  ];
  fhir:MedicinalProductClinicals.undesirableEffects [
     fhir:index 0;
     fhir:MedicinalProductClinicals.undesirableEffects.symptomConditionEffect [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/undesirableeffectassymptom-condition-effect&quot; ];
         fhir:Coding.code [ fhir:value &quot;Anaemia&quot; ]
       ];
       fhir:CodeableConcept.text [ fhir:value &quot;Prevention of\\nVTE in adult\\npatients who have\\nundergone\\nelective hip or\\nknee replacement\\nsurgery (VTEp)&quot; ]
     ];
     fhir:MedicinalProductClinicals.undesirableEffects.classification [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/symptom-condition-effectclassification&quot; ];
         fhir:Coding.code [ fhir:value &quot;Bloodandlymphaticsystemdisorders&quot; ]
       ]
     ];
     fhir:MedicinalProductClinicals.undesirableEffects.frequencyOfOccurrence [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/frequencyofoccurrence&quot; ];
         fhir:Coding.code [ fhir:value &quot;Common&quot; ]
       ]
     ]
  ];
  fhir:MedicinalProductClinicals.therapeuticIndication [
     fhir:index 0;
     fhir:MedicinalProductClinicals.therapeuticIndication.diseaseSymptomProcedure [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/indicationasdisease-symptom-procedure&quot; ];
         fhir:Coding.code [ fhir:value &quot;Venousthromboembolismprophylaxis&quot; ]
       ];
       fhir:CodeableConcept.text [ fhir:value &quot;Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).&quot; ]
     ];
     fhir:MedicinalProductClinicals.therapeuticIndication.comorbidity [
       fhir:index 0;
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/comorbidity&quot; ];
         fhir:Coding.code [ fhir:value &quot;Hipsurgery&quot; ]
       ]
     ];
     fhir:MedicinalProductClinicals.therapeuticIndication.intendedEffect [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/intendedeffect&quot; ];
         fhir:Coding.code [ fhir:value &quot;PRYLX&quot; ]
       ]
     ];
     fhir:MedicinalProductClinicals.therapeuticIndication.population [
       fhir:index 0;
       fhir:MedicinalProductClinicals.undesirableEffects.population.ageRange [
         fhir:Range.low [
           fhir:Quantity.value [ fhir:value &quot;18&quot;^^xsd:decimal ];
           fhir:Quantity.unit [ fhir:value &quot;a&quot; ]
         ]
       ]
     ]
  ];
  fhir:MedicinalProductClinicals.contraindication [
     fhir:index 0;
     fhir:MedicinalProductClinicals.contraindication.disease [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/contraindicationsasdisease-symptom-procedure&quot; ];
         fhir:Coding.code [ fhir:value &quot;Coagulopathiesandbleedingdiatheses(exclthrombocytopenic)&quot; ]
       ];
       fhir:CodeableConcept.text [ fhir:value &quot;Hepatic disease associated with coagulopathy and clinically relevant bleeding risk&quot; ]
     ];
     fhir:MedicinalProductClinicals.contraindication.comorbidity [
       fhir:index 0;
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/comorbidity&quot; ];
         fhir:Coding.code [ fhir:value &quot;Hepaticdisease&quot; ]
       ]
     ]
  ];
  fhir:MedicinalProductClinicals.interactions [
     fhir:index 0;
     fhir:MedicinalProductClinicals.interactions.interaction [ fhir:value &quot;Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.&quot; ];
     fhir:MedicinalProductClinicals.interactions.interactant [
       fhir:index 0;
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/interactant&quot; ];
         fhir:Coding.code [ fhir:value &quot;ketoconazole&quot; ]
       ]
     ], [
       fhir:index 1;
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/interactant&quot; ];
         fhir:Coding.code [ fhir:value &quot;itraconazole&quot; ]
       ]
     ];
     fhir:MedicinalProductClinicals.interactions.type [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/interactionsType&quot; ];
         fhir:Coding.code [ fhir:value &quot;StrongInhibitorofCYP3A4&quot; ]
       ]
     ];
     fhir:MedicinalProductClinicals.interactions.effect [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/interactionseffect&quot; ];
         fhir:Coding.code [ fhir:value &quot;Increasedplasmaconcentrations&quot; ]
       ]
     ];
     fhir:MedicinalProductClinicals.interactions.management [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value &quot;http://ema.europa.eu/example/managementactions&quot; ];
         fhir:Coding.code [ fhir:value &quot;CoadministrationnotrecommendedinpatientsreceivingconcomitantsystemictreatmentstronginhibitorsofbothCYP3A4andP-gp&quot; ]
       ]
     ]
  ] .

# - ontology header ------------------------------------------------------------

&lt;http://hl7.org/fhir/MedicinalProductClinicals/example.ttl&gt; a owl:Ontology;
  owl:imports fhir:fhir.ttl;
  owl:versionIRI &lt;http://build.fhir.org/MedicinalProductClinicals/example.ttl&gt; .

# -------------------------------------------------------------------------------------


</pre>
</div>


<p>
Usage note: every effort has been made to ensure that the
examples are correct and useful, but they are not a normative part 
of the specification. 
</p>

</div>


				</div><!-- /inner-wrapper -->
            </div><!-- /row -->
        </div><!-- /container -->
        
    </div><!-- /segment-content -->


	<div id="segment-footer" class="segment"><!-- segment-footer -->
		<div class="container"><!-- container -->
			<div class="inner-wrapper">
				<p>
        &reg;© HL7.org 2011+. FHIR Release 4 Candidate (v3.5.0-????) generated on Fri, Sep 14, 2018 07:27-0500. <a  style="color: #ffffff" href="qa.html">QA Page</a>
        <br/>
        <span style="color: #FFFF77">
        Links: <a style="color: #b8dcf9" href="http://hl7.org/fhir/search.cfm">Search</a> | 
               <a style="color: #b8dcf9" href="history.html">Version History</a> | 
               <a style="color: #b8dcf9" href="toc.html">Table of Contents</a> | 
               <a style="color: #b8dcf9" href="credits.html">Credits</a> | 
               <a style="color: #b8dcf9" href="http://services.w3.org/htmldiff?doc1=http%3A%2F%2Fhl7.org%2Ffhir%2FSTU3%2Fmedicinalproductindication-example.ttl.html&amp;doc2=http%3A%2F%2Fbuild.fhir.org%2Fmedicinalproductindication-example.ttl.html">Compare to DSTU3</a> |                
               <a style="color: #b8dcf9" href="http://services.w3.org/htmldiff?doc1=http%3A%2F%2Fhl7.org%2Ffhir%2F2018May%2Fmedicinalproductindication-example.ttl.html&amp;doc2=http%3A%2F%2Fbuild.fhir.org%2Fmedicinalproductindication-example.ttl.html">Ballot Comparison</a> |                
               <a style="color: #b8dcf9" rel="license" href="license.html"><img src="cc0.png" style="border-style: none;" alt="CC0"/></a> | 
               <a style="color: #b8dcf9" target="_blank" href="http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemAdd&amp;tracker_id=677">Propose a change</a>   
        </span>
        </p>
			</div><!-- /inner-wrapper -->
		</div><!-- /container -->
	</div><!-- /segment-footer -->
<!-- disqus thread -->
<!--disqus-->
<!-- end disqus -->        
	
	<div id="segment-post-footer" class="segment hidden"><!-- segment-post-footer -->
		<div class="container"><!-- container -->
		</div><!-- /container -->
	</div><!-- /segment-post-footer -->
    
    <!-- JS and analytics only. -->
    <!-- Bootstrap core JavaScript
================================================== -->
<!-- Placed at the end of the document so the pages load faster -->
<script src="./assets/js/jquery.js"> </script>   <!-- note keep space here, otherwise it will be transformed to empty tag -> fails -->
<script src="./dist/js/bootstrap.min.js"> </script>
<script src="./assets/js/respond.min.js"> </script>

<script src="./assets/js/fhir.js"> </script>

<!-- Analytics Below
================================================== -->

    
</body>
</html>
